DOI QR코드

DOI QR Code

Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer

  • Yang, Kyungmi (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bae, Duk-Soo (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Byoung-Gie (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jeong-Won (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2016.07.25
  • Accepted : 2016.09.21
  • Published : 2017.03.31

Abstract

Purpose: The purpose of this study was to analyze clinical outcomes from cervical cancer and stratify patients into risk groups for prognostic factors for early-stage disease. Materials and Methods: We retrospectively reviewed patients with stage IB or IIA cervical cancer treated with adjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) following primary surgery at Samsung Medical Center from 2001 to 2011. Adjuvant RT was added for patients with intermediate-risk factors, and adjuvant CCRT was performed on high-risk patients after surgery. Results: We reviewed 247 patients-149 in the high-risk group and 98 in intermediate-risk group. The median follow-up was 62 months. Loco-regional failure (LRF) alone occurred in 7 patients (2.8%), distant metastasis alone in 37 patients (15.0%) and LRF with DM in 4 patients (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates for both groups were 79.7% and 87.6%, respectively. In the high-risk group, the 5-year DFS and OS probabilities were 72.5% and 81.9%, respectively. Histologic type, pathologic tumor size, and the number of pelvic lymph node (PLN) metastasis were significant prognostic factors for DFS and OS. We suggest a scoring system (0-3) using these prognostic factors to predict poor prognosis in high-risk patients. Using this system, patients with higher scores have higher recurrence and lower survival rates. Conclusion: In the high-risk cervical-cancer group who received primary surgery and adjuvant CCRT, non-squamous type, large tumor size and the number of PLN metastasis were significant prognostic factors, and the number of these factors was associated with survival rates.

Keywords

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41. https://doi.org/10.4143/crt.2015.060
  3. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107-8. https://doi.org/10.1016/j.ijgo.2009.02.009
  4. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13. https://doi.org/10.1200/JCO.2000.18.8.1606
  5. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006;65:169-76. https://doi.org/10.1016/j.ijrobp.2005.10.019
  6. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 1999;73:177-83. https://doi.org/10.1006/gyno.1999.5387
  7. Kim HJ, Rhee WJ, Choi SH, et al. Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer. Radiat Oncol J 2015;33:126-33. https://doi.org/10.3857/roj.2015.33.2.126
  8. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-25. https://doi.org/10.1016/S0140-6736(03)13778-6
  9. Lee YY, Choi CH, Kim TJ, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 2011;120:439-43. https://doi.org/10.1016/j.ygyno.2010.11.022
  10. Noh JM, Park W, Kim YS, et al. Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10). Gynecol Oncol 2014;132:618-23. https://doi.org/10.1016/j.ygyno.2014.01.043
  11. Mabuchi S, Okazawa M, Matsuo K, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol 2012;127:114-20. https://doi.org/10.1016/j.ygyno.2012.06.021
  12. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40. https://doi.org/10.1016/S0140-6736(97)02250-2
  13. Huang YT, Wang CC, Tsai CS, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;84:420-7. https://doi.org/10.1016/j.ijrobp.2011.12.013
  14. Grisaru D, Covens A, Chapman B, et al. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer 2001;92:2999-3004. https://doi.org/10.1002/1097-0142(20011215)92:12<2999::AID-CNCR10145>3.0.CO;2-1
  15. Chung CK, Nahhas WA, Stryker JA, Curry SL, Abt AB, Mortel R. Analysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix. Am J Obstet Gynecol 1980;138:550-6. https://doi.org/10.1016/0002-9378(80)90285-9
  16. Lai CH, Chang HC, Chang TC, Hsueh S, Tang SG. Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases. Gynecol Oncol 1993;51:390-6. https://doi.org/10.1006/gyno.1993.1309
  17. Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE. Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-risk stage IIB cervical carcinoma. Int J Clin Oncol 2004;9:120-4. https://doi.org/10.1007/s10147-003-0378-9
  18. Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer 1999;85:1547-54. https://doi.org/10.1002/(SICI)1097-0142(19990401)85:7<1547::AID-CNCR16>3.0.CO;2-2
  19. Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 1990;65:1923-7. https://doi.org/10.1002/1097-0142(19900501)65:9<1923::AID-CNCR2820650909>3.0.CO;2-M
  20. Choi CH, Lee JW, Kim TJ, et al. Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results. Int J Radiat Oncol Biol Phys 2007;68:817-22. https://doi.org/10.1016/j.ijrobp.2006.12.038
  21. Zhang MQ, Liu SP, Wang XE. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study. Int J Radiat Oncol Biol Phys 2010;78:821-7. https://doi.org/10.1016/j.ijrobp.2009.08.069
  22. Abe A, Furumoto H, Nishimura M, Irahara M, Ikushima H. Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy. Oncol Lett 2012;3:571-6. https://doi.org/10.3892/ol.2011.516
  23. Petric Mise B, Boraska Jelavic T, Strikic A, et al. Long followup of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. Int J Gynecol Cancer 2015;25:315-9. https://doi.org/10.1097/IGC.0000000000000336
  24. Kim HS, Kim MK, Kim HJ, Han SS, Kim JW. Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer. Cancer Res Treat 2012;44:97-103. https://doi.org/10.4143/crt.2012.44.2.97
  25. Mabuchi S, Isohashi F, Yokoi T, et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol 2016;141:240-6. https://doi.org/10.1016/j.ygyno.2016.02.011
  26. ClinicalTrials.gov. Trial of postoperative chemoradiotherapy with or without consolidation chemotherapy for cervical cancer patients (NCT01755845) [Internet]. Bethesda, MD: National Library of Medicine (US); c2016 [cited 2016 May 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01755845?term=01755845&rank=1.
  27. ClinicalTrials.gov. Radiation therapy with or without chemotherapy in patients with stage I or stage II cervical cancer who previously underwent surgery (NCT01101451) [Internet]. Bethesda, MD: National Library of Medicine (US); c2016 [cited 2016 May 1]. Available from: https://clinicaltrials.gov/show/NCT01101451.

Cited by

  1. Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KR vol.147, pp.2, 2017, https://doi.org/10.1016/j.ygyno.2017.08.029
  2. Risk prediction model for disease-free survival in women with early-stage cervical cancers following postoperative (chemo)radiotherapy vol.104, pp.2, 2018, https://doi.org/10.5301/tj.5000697
  3. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional vol.30, pp.1, 2017, https://doi.org/10.3802/jgo.2019.30.e1
  4. Potential Role of lncRNA H19 as a Cancer Biomarker in Human Cancers Detection and Diagnosis: A Pooled Analysis Based on 1585 Subjects vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/9056458
  5. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group vol.45, pp.4, 2019, https://doi.org/10.1016/j.ejso.2018.11.014
  6. Long Non-Coding RNA MALAT1 as a Detection and Diagnostic Molecular Marker in Various Human Cancers: A Pooled Analysis Based on 3255 Subjects vol.13, pp.None, 2017, https://doi.org/10.2147/ott.s250796
  7. Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy vol.157, pp.2, 2017, https://doi.org/10.1016/j.ygyno.2020.02.031
  8. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor vol.31, pp.3, 2017, https://doi.org/10.3802/jgo.2020.31.e35
  9. Who can benefit from a lymph node boost in definitive chemoradiotherapy for node-positive cervical cancer: an evaluation of nodal failure in patients without nodal boost vol.61, pp.3, 2017, https://doi.org/10.1093/jrr/rraa012
  10. Comparison of Outcomes and Prognostic Factors Between Early-Stage Cervical Adenocarcinoma and Adenosquamous Carcinoma Patients After Radical Surgery and Postoperative Adjuvant Radiotherapy vol.13, pp.None, 2017, https://doi.org/10.2147/cmar.s329614
  11. Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features vol.32, pp.5, 2021, https://doi.org/10.3802/jgo.2021.32.e72
  12. Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer vol.53, pp.3, 2017, https://doi.org/10.4143/crt.2020.1251
  13. Ginsenoside Rh2 stimulates the production of mitochondrial reactive oxygen species and induces apoptosis of cervical cancer cells by inhibiting mitochondrial electron transfer chain complex vol.24, pp.6, 2017, https://doi.org/10.3892/mmr.2021.12513
  14. Predicting Tumor Budding Status in Cervical Cancer Using MRI Radiomics: Linking Imaging Biomarkers to Histologic Characteristics vol.13, pp.20, 2021, https://doi.org/10.3390/cancers13205140